Recent clinical study findings highlight how Implandata’s EYEMATE system is transforming glaucoma treatment at a time when patients are hampered in visiting vision care providers. As reported in the journal Ophthalmology Glaucoma, eye specialists remotely monitored the intraocular pressure (IOP) of their patients during a lockdown period. Based on data generated by the EYEMATE system, doctors changed the therapy of 29% of their patients without requiring an office visit – thus reducing the risk of vision loss and keeping them safe during the lockdown.
EYEMATE is a CE-marked, clinically-validated system for continual, remote monitoring and management of glaucoma patient care. Implandata’s proprietary biosensors and cloud-based, AI-system alert patients and their eye doctor in real-time of uncontrolled glaucoma, enabling real-time therapy adjustment to prevent vision loss.
Undetected disease progression is a big risk. Glaucoma gradually robs people of their vision. Continual, remote monitoring of glaucoma patients allows early therapy adjustment as needed, even when glaucoma patients are unable to visit their eye doctor. Thus, EYEMATE enables patients and their eye doctors to be informed in real-time of disease progression, which means the therapy can be adjusted without delay – before eyesight is permanently lost.
Kaweh Mansouri, M.D., lead investigator of the study, ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland and Professor at the Department of Ophthalmology at University of Colorado, explains: “Our study shows that unnecessary clinic visits can be avoided by remote glaucoma monitoring. This is particularly important during the current pandemic for elderly patients who are at highest risk for COVID-19 complications.”
Robert N. Weinreb, M.D., Chair and Distinguished Professor of Ophthalmology at University of California, San Diego adds: “The study findings help us envisage a future for tele-ophthalmology in glaucoma management far beyond the COVID-19 pandemic. Remote patient monitoring and management significantly enhance existing glaucoma diagnostics, and allows a more rational application of existing and future vision-saving therapies.”
Full news release: www.b3cnewswire.com/202101182171/implandata-s-eyemate-system-protects-glaucoma-patients-even-during-lockdown.html